1887
  1. Home
  2. Eurosurveillance
  3. Volume 26, Issue 27, 08/Jul/2021
  4. Article
Rapid communication Open Access
Like 0
Download

Abstract

We compared the performance of SARS-CoV-2 neutralising antibody testing between 12 European laboratories involved in convalescent plasma trials. Raw titres differed almost 100-fold differences between laboratories when blind-testing 15 plasma samples. Calibration of titres in relation to the reference reagent and standard curve obtained by testing a dilution series reduced the inter-laboratory variability ca 10-fold. The harmonisation of neutralising antibody quantification is a vital step towards determining the protective and therapeutic levels of neutralising antibodies.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2021.26.27.2100568
2021-07-08
2024-04-18
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2021.26.27.2100568
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/26/27/eurosurv-26-27-2.html?itemId=/content/10.2807/1560-7917.ES.2021.26.27.2100568&mimeType=html&fmt=ahah

References

  1. Kellam P, Barclay W. The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection. J Gen Virol. 2020;101(8):791-7.  https://doi.org/10.1099/jgv.0.001439  PMID: 32430094 
  2. Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M, et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science. 2020;370(6521):1227-30.  https://doi.org/10.1126/science.abd7728  PMID: 33115920 
  3. McMahan K, Yu J, Mercado NB, Loos C, Tostanoski LH, Chandrashekar A, et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature. 2021;590(7847):630-4.  https://doi.org/10.1038/s41586-020-03041-6  PMID: 33276369 
  4. Rogers TF, Zhao F, Huang D, Beutler N, Burns A, He WT, et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science. 2020;369(6506):956-63.  https://doi.org/10.1126/science.abc7520  PMID: 32540903 
  5. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021.  https://doi.org/10.1038/s41591-021-01377-8  PMID: 34002089 
  6. Taylor PC, Adams AC, Hufford MM, de la Torre I, Winthrop K, Gottlieb RL. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev Immunol. 2021;21(6):382-93.  https://doi.org/10.1038/s41577-021-00542-x  PMID: 33875867 
  7. Piechotta V, Iannizzi C, Chai KL, Valk SJ, Kimber C, Dorando E, et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database Syst Rev. 2021;5(5):CD013600. PMID: 34013969 
  8. Focosi D, Franchini M. Potential use of convalescent plasma for SARS-CoV-2 prophylaxis and treatment in immunocompromised and vulnerable populations. Expert Rev Vaccines. 2021;1-8. PMID: 34015243 
  9. Libster R, Pérez Marc G, Wappner D, Coviello S, Bianchi A, Braem V, et al. Early high-titer plasma therapy to prevent severe Covid-19 in older adults. N Engl J Med. 2021;384(7):610-8.  https://doi.org/10.1056/NEJMoa2033700  PMID: 33406353 
  10. Hueso T, Pouderoux C, Péré H, Beaumont AL, Raillon LA, Ader F, et al. Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19. Blood. 2020;136(20):2290-5.  https://doi.org/10.1182/blood.2020008423  PMID: 32959052 
  11. Körper S, Weiss M, Zickler D, Wiesmann T, Zacharowski K, M.Corman V, et al. High dose convalescent plasma in COVID-19: results from the randomized trial CAPSID. medRxiv. 2021:2021.05.10.21256192.
  12. Kristiansen PA, Page M, Bernasconi V, Mattiuzzo G, Dull P, Makar K, et al. WHO International Standard for anti-SARS-CoV-2 immunoglobulin. Lancet. 2021;397(10282):1347-8.  https://doi.org/10.1016/S0140-6736(21)00527-4  PMID: 33770519 
  13. Cele S, Gazy I, Jackson L, Hwa SH, Tegally H, Lustig G, et al. Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma. Nature. 2021;593(7857):142-6.  https://doi.org/10.1038/s41586-021-03471-w  PMID: 33780970 
  14. Wibmer CK, Ayres F, Hermanus T, Madzivhandila M, Kgagudi P, Oosthuysen B, et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat Med. 2021;27(4):622-5.  https://doi.org/10.1038/s41591-021-01285-x  PMID: 33654292 
  15. Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol. 2021;19(7):409-24.  https://doi.org/10.1038/s41579-021-00573-0  PMID: 34075212 
  16. Abani O, Abbas A, Abbas F, Abbas M, Abbasi S, Abbass H, et al. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet. 2021;397(10289):2049-59.  https://doi.org/10.1016/S0140-6736(21)00897-7  PMID: 34000257 
  17. Ratcliff J, Nguyen D, Fish M, Rynne J, Jennings A, Williams S, et al. Virological and serological characterization of critically ill patients with COVID-19 in the UK: Interactions of viral load, antibody status and B.1.1.7 variant infection. J Infect Dis. 2021;jiab283.  https://doi.org/10.1093/infdis/jiab283  PMID: 34031695 
  18. Perera RA, Mok CK, Tsang OT, Lv H, Ko RL, Wu NC, et al. Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020. Euro Surveill. 2020;25(16):2000421.  https://doi.org/10.2807/1560-7917.ES.2020.25.16.2000421  PMID: 32347204 
SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Dung+Nguyen&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Nguyen Dung</a>, <a href="/search?value1=Peter+Simmonds&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Simmonds Peter</a>, <a href="/search?value1=Maurice+Steenhuis&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Steenhuis Maurice</a>, <a href="/search?value1=Elise+Wouters&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Wouters Elise</a>, <a href="/search?value1=Daniel+Desmecht&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Desmecht Daniel</a>, <a href="/search?value1=Mutien+Garigliany&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Garigliany Mutien</a>, <a href="/search?value1=Marta+Romano&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Romano Marta</a>, <a href="/search?value1=Cyril+Barbezange&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Barbezange Cyril</a>, <a href="/search?value1=Piet+Maes&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Maes Piet</a>, <a href="/search?value1=Bram+Van+Holm&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Van Holm Bram</a>, <a href="/search?value1=Joaqu%C3%ADn+Mendoza&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Mendoza Joaquín</a>, <a href="/search?value1=Salvador+Oyonarte&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Oyonarte Salvador</a>, <a href="/search?value1=Anders+Fomsgaard&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Fomsgaard Anders</a>, <a href="/search?value1=Ria+Lassauni%C3%A8re&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Lassaunière Ria</a>, <a href="/search?value1=Eva+Zusinaite&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Zusinaite Eva</a>, <a href="/search?value1=Katarina+Resman+Rus&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Resman Rus Katarina</a>, <a href="/search?value1=Tatjana+Av%C5%A1i%C4%8D-%C5%BDupanc&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Avšič-Županc Tatjana</a>, <a href="/search?value1=Johan+HJ+Reimerink&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Reimerink Johan HJ</a>, <a href="/search?value1=Fiona+Brouwer&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Brouwer Fiona</a>, <a href="/search?value1=Marieke+Hoogerwerf&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Hoogerwerf Marieke</a>, <a href="/search?value1=Chantal+BEM+Reusken&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Reusken Chantal BEM</a>, <a href="/search?value1=Gunnveig+Grodeland&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Grodeland Gunnveig</a>, <a href="/search?value1=Sophie+Le+Cam&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Le Cam Sophie</a>, <a href="/search?value1=Pierre+Gallian&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Gallian Pierre</a>, <a href="/search?value1=Abdennour+Amroun&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Amroun Abdennour</a>, <a href="/search?value1=Nad%C3%A8ge+Brisbarre&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Brisbarre Nadège</a>, <a href="/search?value1=Christophe+Martinaud&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Martinaud Christophe</a>, <a href="/search?value1=Isabelle+Leparc+Goffart&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Leparc Goffart Isabelle</a>, <a href="/search?value1=Hubert+Schrezenmeier&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Schrezenmeier Hubert</a>, <a href="/search?value1=Hendrik+B+Feys&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Feys Hendrik B</a>, <a href="/search?value1=C+Ellen+van+der+Schoot&option1=author&noRedirect=true" class="nonDisambigAuthorLink">van der Schoot C Ellen</a>, <a href="/search?value1=Heli+Harvala&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Harvala Heli</a></span>. SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data. <a href="/content/ecdc">Euro Surveill.</a> 2021;26(27):pii=2100568. <a href="https://doi.org/10.2807/1560-7917.ES.2021.26.27.2100568" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2021.26.27.2100568</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 11 Jun 2021;&nbsp;&nbsp; <span class="generated">Accepted</span>: 05 Jul 2021 </span> </p>
/content/10.2807/1560-7917.ES.2021.26.27.2100568
/content/10.2807/1560-7917.ES.2021.26.27.2100568
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error